If you watch a lot of combat sports, you probably know that fighters take a risk every time they step into the ring. This is because fighters know, whether they’re in the UFC Octagon or a typical boxing ring, they’re going to get hit in the head. It doesn’t matter what causes the hit —an elbow, knee, foot or fist — the brain still suffers trauma.
Despite strides that have been made in research to understand why and how trauma is caused, as well as the long-term impact of said trauma, much about brain injuries remains unknown.
Currently, new research is being conducted in a bid to find out how these injuries sustained by combat sports competitors could be treated. Recent reports have shown that the UFC is looking into research about microdosing psychedelics. In addition to this, the UFC has had discussions with Johns Hopkins University about the facility’s research on psychedelics to see if the drugs could benefit fighters who are battling brain issues.
The Ultimate Fighting Championship (“UFC”) has been a big financial backer of a professional athlete brain study being carried out at the Cleveland Clinic Lou Ruvo Center for Brain Health; the organization’s most recent contribution totaled $1 million.
Another company that is strongly interested in this research Revive Therapeutics. The company, which is based in Toronto, is centered on research as well as the development of remedies for rare disorders and infectious ailments. Revive Therapeutics has prioritized its drug-development efforts as a way to take advantage of various regulatory incentives awarded by the Food and Drug Administration such as Rare Pediatric Disease, Breakthrough Therapy, Fast Track and Orphan Drug designations.
Revive is currently exploring the use of bucillamine as a potential treatment for infectious ailments such as severe influenza and the novel coronavirus. The company also acquired Psilocin Pharma Corp. recently, which will aid greatly in its advancement of the development of psilocybin-based therapeutics for various disorders and diseases.
Additionally, the company’s portfolio for cannabinoid pharmaceuticals focuses on finding solutions to rare inflammatory ailments. Revive was granted the Orphan Drug designation by the FDA for its intention to use CBD to treat reperfusion injury stemming from the organ transplant process and auto immune hepatitis.
Revive Therapeutics CEO Michael Frank has stated that the company was excited that the UFC was showing interest in the use of psilocybin for brain-injury treatment.
More companies are recognizing and understanding the need to help those dealing with brain issues. While it’s too early to know how controlled micro-dosing psychedelic regimens can be implemented, it’s encouraging and motivating to realize that a new and better way to help athletes manage their conditions and live after competing is being developed, which gives hope to fighters in need of assistance.
As this research is going on, California-based Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) has a facility spanning 10,000 square feet. This facility is EU-GMT compliant, so the company can manufacture and market its functional mushroom and medicinal psychedelic products within EU guidelines.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
